Denmark's RSV maternal vaccine program cuts infant hospitalizations sharply
Denmark began nationwide RSV vaccination of pregnant people on 1 October 2025, aiming to pass protective antibodies to newborns through the placenta, while unvaccinated mothers' high-risk infants received monoclonal antibody injections instead. Epidemiologist Caroline Klint Johannesen's analysis of Danish hospital records found a sharp drop in infant RSV hospital admissions following the rollout.
GoKawiil's interpretation of the reporting above, not reported fact.
The results suggest that combining maternal vaccination with monoclonal antibodies for unprotected newborns can substantially reduce severe RSV disease in infants, a group that accounts for millions of hospitalizations and roughly 100,000 child deaths worldwide each year according to WHO estimates. Since the WHO notes 97% of pediatric RSV deaths occur in low- and middle-income countries, Denmark's early results could strengthen arguments for expanding similar programs beyond wealthy nations, though cost and infrastructure barriers remain unaddressed in the data so far.
- Denmark's nationwide maternal RSV vaccination policy began 1 October 2025.
- Early hospital data show a steep drop in infant RSV admissions since the rollout.
- WHO estimates 97% of RSV deaths in children under 5 occur in low- and middle-income countries, raising questions about global access.
Source: nature.com — Drew, 2026-11-12
Published there as: “RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.